Purpose We investigated the clinical relevance and spectrum of BRCA1/2 mutations in Korean ovarian cancer (KoOC) patients.
Introduction
Epithelial ovarian cancer (EOC) is the leading cause of cancer-related deaths in women worldwide and remains the most lethal gynecological cancer [1] . Although the incidence of EOC has traditionally been lower in Korea than in western countries, including the United States and United Kingdom, it has steadily increased over the last few decades because of lifestyle and environmental changes [2] . In 1999, the agestandardized rates for annual EOC incidence and mortality in Korea were 5.0 and 1.7 per 100,000 women-years, respectively, which significantly increased to 6.4 and 2.3 per 100,000 women-years, respectively, by 2014 (both, p < 0.05) [3] . Such increases represent a significant challenge to overcome, and methods for controlling the increasing rates of this cancer are urgently needed.
Defects in BRCA1/2 tumor suppressor genes are the most frequently identified genetic changes associated with ovarian cancer. A BRCA1/2 germline mutation is associated with poor prognostic factors, including early-onset cancer, serous histology, and advanced cancer stages [4] . However, in recent years, accumulating evidence has shown that BRCA1/2 mutations are associated with improved survival and improved response to not only platinum-based chemotherapy [5, 6] but also targeted therapy using poly(ADP-ribose) polymerase inhibitors [7, 8] .
Although there have been several reports of BRCA1/2 mutation analyses in ovarian and breast cancer cases from Asian populations, there is relatively limited data for the Korean ovarian cancer (KoOC) population. Until now, there have been four independent studies on BRCA1/2 mutations in KoOC patients; however, all of these were relatively smallscale, single-center studies with marked inter-study heterogeneity among their results [9] [10] [11] . Furthermore, there has been no spectrum study of BRCA1/2 mutations in KoOC patients, such as nation-wide the Korean Hereditary Breast Cancer (KOHBRA) study [12, 13] ; KOHBRA study included a total of 2,953 breast cancer patients with high risk of hereditary breast and ovarian cancer (HBOC) enrolled from 36 institutions between 2007 and 2013, covering approximately 2.9% of the total Korean breast cancer (KoBC) patients during the study period. Thus, we performed comprehensive analyses to estimate the prevalence, clinicopathological significance, spectrum, and penetrance of BRCA1/2 mutations in a large cohort of KoOC patients.
Materials and Methods

Patients
A total of 279 EOC patients unselected for family history (FH) were enrolled between May 2012 and December 2017 from three investigational sites in Korea: the Pusan National University Hospital, Inje University Paik Hospital, and Kosin University Gospel Hospital (PIKO). Genetic testing of BRCA1/2 genes in all three investigational hospitals was carried out by the Green Cross Company (Yongin, Korea) during the study period. The inclusion criteria for enrollment were primary EOC patients who had undergone staging surgery and had pathologically confirmed with EOC. Clinical and pathological data were collected for all patients: age at diagnosis, EOC grade, lymph node (LN) metastasis, FIGO stage (International Federation of Gynecology and Obstetrics, 2013), and personal history and FH of cancer. Patients with FH were defined as those with primary breast cancer or with first-or second-degree relatives with breast or ovarian cancer. FH of other cancer include all type of hematologic and non-hematologic malignancies.
Direct sequencing
Genomic DNA was obtained from peripheral blood leukocytes and was extracted using the Promega DNA purification kit (catalog No. LA1620, Madison, WI) according to the manufacturer's instructions. All exon and intron boundaries of BRCA1/2 were analyzed for mutations using a combination of denaturing high-performance liquid chromatography (WAVE DNA Fragment Analysis System, Transgenomic Inc., San Jose, CA) and bi-directional sequencing with a Big Dye Terminator V3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA) and ABI 3500xl (Life Technologies).
Statistical analyses
The Human Genome Variation Society nomenclature system (http://www.hgvs.org/mutnomen) was used for describing sequence variations, and the Breast Cancer Information Core (BIC) database (http://research.nhgri.nih.gov/projects /bic/Member/index.shtml) was used for evaluating results. Relationships among categorical variables were evaluated using t or chi-square tests. For all analyses, a p-value < 0.05 was considered statistically significant. Analyses were performed using SPSS ver. 20.0 (IBM Corp., Armonk, NY). Values are presented as number (%) or mean±standard deviation. FHBOC, family history of breast/ovarian cancer; FH, family history; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node. a) Continuous variables were analyzed using the Student's t test; categorical variables were analyzed using the chi-square test, b) Patients with primary breast cancer or first-or second-degree relatives with breast or ovarian cancer.
B A
Ethical statement
This study was approved by the institutional review boards of the abovementioned three institutions. Informed consent was obtained from all participants, and peripheral blood samples were collected from each subject.
Results
Prevalence of BRCA1/2 mutations
In our direct sequencing analysis of BRCA1/2 genes in the 279 unselected EOC patients, pathogenic BRCA1 and BRCA2 mutations were observed in 35 (12.6%) and 11 (3.9%) cases, respectively. The overall prevalence of BRCA1/2 mutations in KoOC patients was 16.5% (Fig. 1A ). Among the 279 EOC patients, 60 patients (21.5%) had FH of breast or ovarian cancer and 219 (78.5%) did not. The prevalence of BRCA1/2 mutations was higher in the former (21 of 60, 35.0%) than in the latter (27 of 219, 12.3%) (Fig. 1B) . In specific subgroups according to tumor histology (serous vs. non-serous) and FIGO stage (I/II vs. III/IV), the prevalence of BRCA1/2 mutations was 11.9 % in patients with early stage (I/II) and serous histology, 23.1% in patients with advanced stage (III/IV) and serous histology, 0% in patients with early stage (I/II) and non-serous histology and 16.7% in patients with advanced stage (III/IV) and non-serous histology (S1 Fig.) .
Clinical characteristics of BRCA1/2 mutations
Relationships between clinicopathological characteristics and BRCA1/2 mutations are listed in Table 1 . The mean ages at the time of onset for patients with and without BRCA1/2 mutations were 53.7±9.6 years and 54.2±10.9 years, respectively, with no significant difference between them (p=0.765). In addition, we found no significant difference in the proportion of patients with early age-of-onset (< 50 years) of ovarian cancers between BRCA1/2 mutation carriers and non-carriers (39.1% vs. 30.5%, p=0.223). Patients with BRCA1/2 mutations exhibited significantly higher rates of FH of breast or ovarian cancer (45.7%) and other cancers (39.1%) compared with those without BRCA1/2 mutations (16.7% for FH of breast or ovarian cancer; 18.5% for FH of other cancers; both, p < 0.001). The occurrence of serous histology was significantly higher in patients with BRCA1/2 mutations (91.3%) than in those without BRCA1/2 mutations (68.7%, p=0.002). Four patients with BRCA1/2 mutations (8.7%) were identified as having non-serous histology in this study, with three cases of clear cell-type histology with BRCA1 mutations and one case of endometrioid-type histology with a BRCA2 mutation (S2 Table) . In addition, patients with BRCA1/2 mutations were more likely to be at an advanced FIGO stage of III/IV (87.0%) and exhibit LN metastasis (48.8%) than those without BRCA1/2 mutations (61.4%, p=0.007 for advanced FIGO stage of III/ IV; 28.8%, p=0.011 for LN metastasis) (Table 1) . However, multivariate analysis using logistic regression identified FH of breast/ovarian cancer (p < 0.001), serous histology (p=0.044), and advanced FIGO stage (III/IV, p=0.018) as the only factors showing independent correlation with BRCA1/2 mutations (p < 0.05) ( Table 2 ).
Spectrum of BRCA1/2 mutations
All 46 pathogenic BRCA1/2 mutations detected in this study are listed and summarized in S2 Table. Thirty-two distinct mutations were identified, including 21 in BRCA1 and 11 in BRCA2. For a comprehensive analysis of the BRCA1/2 mutation spectrum, all mutations reported in KoOC patients thus far were investigated and have been summarized in Recently implicated as a deleterious mutation rather than a variant of unknown significance. (Fig. 2A) . BRCA1 mutations were more prevalent than BRCA2 mutations, with a BRCA1-to-BRCA2 prevalence ratio of 3.6:1. Of the 111 BRCA1/2 mutations, 55 distinct mutations were identified, including 39 BRCA1 and 16 BRCA2 mutations. Among these pathologic 55 mutations, 24 (43.6%) were specific to Korean women and have not been previously reported in the BIC database (Fig. 2C) . Ten Korean population-specific mutations (18.2%) have not yet been reported in the KOHBRA study. Nineteen distinct mutations (19/55 distinct, 34.5%) were recurrent and were detected in at least two unrelated patients (Fig. 2D ). Of these recurrent mutations, five were highly recurrent and were found more than five times in unrelated patients: c.3627insA (n=14), c.390C>A (n=8), c.922_923AGCinsT (n=5), c.5339T>C (n=5), and c.3442delG (n=5) ( Table 4 ). These five recurrent mutations account for 33.3% (37 of 111) of the mutations detected in the Korean population. These highly recurrent mutations were considered to be most likely the founder mutations in KoOC, and all of these have been reported in the KOHBRA study (Table 4) .
Discussion
In this study, we included 279 unselected EOC patients and comprehensively evaluated BRCA1/2 mutations in the largest multicenter Korean cohort to date. We also analyzed the BRCA1/2 mutation spectrum, including all mutation variants previously reported in KoOC. Across previous studies in Korea, the frequency of BRCA1/2 mutations has reportedly been quite diverse, ranging between 23.8% and 31.9% [9] [10] [11] (S3 Table) ; this variation could have been caused by interstudy heterogeneity, including the differences in sample size, inclusion criteria, and the methods used for detecting mutation. In the present study, the overall frequency of BRCA1/2 mutations in unselected KoOC patients was 16.5% (Fig. 1A) , which was comparable to the frequency of 13% to 15% in western cohorts [6, 14, 15] . In addition, the frequency of BRCA1/2 mutations observed in the present study was comparable to the frequencies reported in other recent Asian reports, ranging from 11% to 17% [16] [17] [18] . These data suggest that there are no marked ethnic differences in the frequency of BRCA1/2 mutations.
In terms of the age-of-onset, patients with BRCA1/2 mutation are characterized by developing EOC at a younger age, based on a report of western cohorts [6] . Unlike the data for western cohorts, in this study, the mean age of patients with BRCA1/2 mutation was not significantly lower than that of those without BRCA1/2 mutation (53.7±9.6 years vs. 54.2±10.9 years, p=0.765). There were no significant differences in the proportion of patients with early age-of-onset (< 50 years) of ovarian cancer between BRCA1/2 mutation carriers and noncarriers (39.1% vs. 30.5%, p=0.223) in KoOC patients. Similarly to the present study, other studies including Asian populations have also shown no significant difference in the mean age-of-onset based on the presence or absence of BRCA1/2 mutation [16] [17] [18] . Difference of genetic background and non-genetic factors, such as birth cohort and reproductive and lifestyle-related factors, could have influenced different results in Asian EOC patients.
Regarding the clinicopathological findings, patients with BRCA1/2 mutations are characterized by serous histology [6, 19] and advanced stage with unfavorable outcomes [6, 19, 20] . In the present study, 91.3% (42/46 BRCA1/2 mutation cases) had serous histology (Table 1) . Only four cases (8.7%) with non-serous histology were identified, comprising three cases with clear carcinoma and one with endometrioid carcinoma. We did not find any other mucinous or mixed types (S2 Table) . The fraction of serous carcinoma in KoOC patients with BRCA1/2 mutation was comparable to those Byung Su Kwon, BRCA1/2 Mutations in KoOC Patients Recently implicated as a deleterious mutation rather than a variant of unknown significance.
previously mentioned in some western reports. Our study also found that BRCA1/2 mutations were significantly associated with an advanced FIGO stage of III/IV (p=0.007) and LN metastasis (p=0.011) ( Table 1 ); in case of LN metastasis, it was not significant in multivariate logistic regression (Table 2) .
Recently, two relatively large population-based studies including 95 and 916 women with unselected ovarian cancer were performed in Japan [17] and China [18] , respectively, which are geographically close to Korea. On comparing three studies of East Asian populations, including the present Korean study, we found no marked ethnic differences in the BRCA1/2 mutation frequency among the studies (12.6% in Japan, 16 .7% in China, and 16.5% in Korea) ( Table 5) . These East Asian studies showed no significant difference in the mean age-of-onset between BRCA1/2 mutation carriers and non-carriers (Japan, 57 years vs. 55 years; China, 53 years vs. 54 years; and Korea, 53 years vs. 54 years) ( Table 5 ). In addition, these three studies revealed significant associations between BRCA1/2 mutation and clinicopathological characteristics, including serous histology and advanced FIGO stage (Table 5) . However, compared with EOC patients with BRCA1/2 mutation in Korea and China, those in Japan showed a lower frequency of BRCA1/2 mutation and higher mean age of onset. The high frequency of BRCA2 mutations and the low proportion of FH of ovarian and/or breast cancer in Japanese EOC patients may have led to these differences in results, possibly indicating that the BRCA1/2 mutation spectrum and/or founder mutations in Japanese EOC patients markedly differ from those in the other two countries.
Although only a few single-center studies including KoOC patients have been done, a large majority of spectrum analysis of BRCA1/2 mutations in Korean HBOC patients was performed by the nationwide KOHBRA study [12, 13] . Among the 2,403 index patients, 378 were found to carry BRCA1/2 mutations. Overall, 153 distinct mutations were identified, including 63 in BRCA1 and 90 in BRCA2. When the BRCA1/2 mutation spectrum was compared between KoOC and KoBC patients, the BRCA1-to-BRCA2 ratio was 3.6:1.0 in KoOC and 1.0:1.4 in KoBC patients, representing that BRCA1 mutations (78.4%) were predominant in KoOC ( Fig. 2A) , whereas BRCA2 mutations (59.2%) were predominant in KoBC (Fig. 2B ). In the KOHBRA study, a replacement mutation, c.7480C>T, in the BRCA2 gene, which was identified as a Korean founder mutation through haplotype analysis by Seong et al. [21] , was the most commonly detected mutation, accounting for 10.1% of all BRCA1/2 mutations (Fig. 2B) . In the present study of KoOC patients, c.3627insA in the BRCA1 gene, was the most commonly detected mutation, accounting for 12.6% of all BRCA1/2 mutations ( Fig. 2A) , and c.7480C> T was identified in only four unrelated EOC patients, accounting for 3.6% of all BRCA1/2 mutations (Table 3) . In our study, the BRCA1/2 mutation spectrum varied according to the cancer type (ovarian and breast cancers) among the Korean HBOC population. The inconsistency of the BRCA1/2 mutation spectrum between ovarian cancer and breast cancer in Korean HBOC was an unexpected result. Previously, Rebbeck et al. [22] investigated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position in the international sample comprised of 19,581 BRCA1/2 mutation carriers from 55 centers in 33 countries on six continents. They identified three breast cancer cluster regions (BCCRs) and one ovarian cancer cluster region (OCCR) in BRCA1 and three BCCRs and three OCCRs in BRCA2, suggesting that breast and ovarian cancer risks were different Cancer Res Treat. 2019;51(3):941-950 Cases with unknown stage (n=56) were excluded.
